Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Rhea-AI Summary

Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 13th at 2:35 PM PDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.

News Market Reaction – CRBU

+0.76%

+0.76% Session move

In the trading session that priced this news, CRBU gained 0.76%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13^th at 2:35 PM PDT.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

FAQ

When is Caribou Biosciences (CRBU) presenting at the BofA Securities Health Care Conference 2025?

Caribou Biosciences will present at the BofA Securities Health Care Conference on May 13th, 2025, at 2:35 PM PDT.

Who will represent Caribou Biosciences (CRBU) at the BofA Securities conference?

Rachel Haurwitz, PhD, who serves as Caribou's president and chief executive officer, will represent the company in a fireside chat.

How long will the CRBU conference webcast be available for viewing?

The webcast will be available on Caribou's website for at least 30 days after the event.

What type of company is Caribou Biosciences (CRBU)?

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company.